Results 111 to 120 of about 13,617 (225)

Omalizumab: what benefits should we expect?

, 2016
Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy.
Armario Hita, Jose Carlos, Labrador-Horrillo, Moisés, Giménez Arnau, Anna Maria, Silvestre Salvador, Juan Francisco, Giménez-Arnau, Ana, Velasco, Manel   +5 more
core   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado   +33 more
wiley   +1 more source

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Case Reports in Medicine, 2015
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria.
Misbah Nasheela Ghazanfar, Simon Francis Thomsen   +1 more
doaj   +1 more source

Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: The Australian Xolair Registry

, 2016
Background: Severe asthma is a high impact disease. Omalizumab targets the allergic inflammatory pathway; however, effectiveness data in a population with significant comorbidities are limited.
Sutherland, M, Rimmer, J, Gibson, PG, Upham, J, Katsoulotos, GP, Cook, M, Sivakumaran, P, Gillman, A, Reddel, H, Thien, F, Marks, G, Yang, I, McDonald, VM, et al., Jenkins, C   +14 more
core   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source

Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

, 2016
Background: Omalizumab (Xolair) dosing in severe allergic asthma is based on serum IgE and bodyweight. In Australia, patients eligible for omalizumab but exceeding recommended ranges for IgE (30–1500 IU/mL) and bodyweight (30–150 kg) may still receive a ...
Sutherland, M, Bowden, J, Rimmer, J, Wark, P, Katsoulotos, GP, Cook, M, Sivakumaran, P, Gillman, A, Thien, F, Guo, M, Marks, GB, Reddel, HK, Hew, M, et al., Jenkins, C   +14 more
core   +1 more source

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

British Journal of Haematology, EarlyView.
Isabel C. Vallecillo‐Viejo, Michael D. Claiborne, Charles F. Anderson, Samantha Shafer, Alan Saven, Bryce A. Seifert, Morgan Similuk, Magdalena Walkiewicz, Irina Maric, Pia R. Crespo, Lori Broderick, Andrew A. White, Amy D. Klion   +12 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Anafilaxia idiopática recurrente tratada con omalizumab

, 2019
Resumen: La anafilaxia es una reacción sistémica grave y potencialmente mortal que ocurre habitualmente de forma inmediata tras la exposición a un alérgeno.
José Luis Cubero Saldaña, Carlos Colás Sanz, Ana Agulló-García   +2 more
core   +1 more source